PharmaCyte Biotech reported QQ1 2026 with no reported revenue and a net loss of 8.36 million USD, driven predominantly by a substantial non-operating expense of 7.51 million and a negative total other income/expenses of 7.51 million. Operating activity generated a modest cash burn (CFO of -1.99 million) and the company ends the quarter with cash and equivalents of 13.18 million USD. The balance sheet shows a sizable portfolio of long-term investments (24.45 million) and intangible assets (1.55 million), with total assets of 45.11 million and stockholders’ equity of 43.59 million, but retains a meaningful accumulated deficit and a notable non-operating liability structure reflected in the reported metrics. The near-term liquidity remains robust relative to current liabilities, but the path to profitability remains highly dependent on external financing or meaningful scientific milestones. Management commentary (where available) would be pivotal to gauge readiness for potential partnerships, licensing opportunities, or readouts from the CellinaBox platform when and if clinical or preclinical catalysts arise. Absent concrete revenue or binding licensing deals, the core valuation driver remains the company’s ability to secure future funding and monetize its asset base through strategic collaborations or portfolio monetization.
Key Performance Indicators
Operating Income
Increasing
-848.31K
QoQ: 11.66% | YoY: 73.21%
Net Income
Decreasing
-8.36M
QoQ: -174.52% | YoY: -720.65%
EPS
Decreasing
-1.23
QoQ: -179.55% | YoY: -823.53%
Revenue Trend
Margin Analysis
Financial Highlights
Key quarterly metrics and trend context:
- Revenue: None reported in QQ1 2026 (revenue and cost of revenue both listed as null in the data provided).
- Operating Income: -0.848 million USD for QQ1 2026, showing a continued operating loss but a modest quarterly deterioration/improvement relative to prior periods as indicated by a QoQ change listed as 11.66% (the negative sign remains, so the QoQ percentage reflects the rate of change in negative territory).
- Net Income: -8.360 million USD for QQ1 2026, with YoY and QoQ changes shown as -720.65% and -174.52% respectively, indicating a much larger annual loss versus the prior year, and a largerquarterly loss versus the prior quarter.
- EPS (Diluted): -1.23 USD for QQ1 2026, with YoY -823.53% and QoQ -179.55%.
Observations on profitability and cash flow:
- EBITDA: -0.848 million USD, with total other income/expenses net at -7.51179 million USD.
- Net income loss is dominated by non-operating items rather than core operations, given the null revenue and substantive other income/expense line.
- Cash flow from operating activities: -1.99398 million USD; cash at period-end: 13.1783 million USD; cash at beginning: 15.1722 million USD; net change in cash: -1.99386 million, with foreign exchange effects contributing +0.000123 million.
- Free cash flow: -1.99398 million USD (reflecting the operating cash flow and lack of meaningful investing cash flow activity in the period).
- Balance sheet liquidity: total current assets 19.1063 million USD versus total current liabilities 1.060865 million USD, yielding a robust current ratio (~18x) under the quarter’s reported figures.
- Net debt position: net debt is negative (net cash) at -13.1783 million USD, indicating liquidity headroom despite ongoing operating losses.
Income Statement
Metric
Value
YoY Change
QoQ Change
Operating Income
-848.31K
73.21%
11.66%
Net Income
-8.36M
-720.65%
-174.52%
EPS
-1.23
-823.53%
-179.55%
Key Financial Ratios
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.